Diagnostic immunohistochemistry in neuromuscular disorders

Histopathology

Volumn 46, Issue 1, 2005, Pages 1-23

  Tews, Dominique S ^a,c   Goebel, H H ^b  

^a GOETHE UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Immunohistochemistry; Muscle fibre; Neuromuscular diseases; Proteins; Western blot

Indexed keywords

CELL ADHESION MOLECULE; NUCLEAR PROTEIN;

CELL INFILTRATION; CLINICAL FEATURE; DENERVATION; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DOMINANT INHERITANCE; ENZYME DEFECT; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; MUSCLE CELL; NEUROMUSCULAR DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECESSIVE INHERITANCE; RELIABILITY; REVIEW; SARCOLEMMA; SARCOMERE; TREATMENT PLANNING; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; FORECASTING; HUMANS; IMMUNOHISTOCHEMISTRY; MUSCLE FIBERS; MUSCLE PROTEINS; NEUROMUSCULAR DISEASES;

EID: 13244249952     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02025.x     Document Type: Review

References (232)

1. Hoffman EP, Kenneth KH, Brown RH et al. Characterization of dystrophin in muscle biopsy specimens from patients with Duchenne muscular dystrophy. N. Engl. J. Med. 1988; 318; 1363-1368.
2. Sewry CA. Immunocytochemical analysis of human muscular dystrophy. Microsc. Res. Techn. 2000; 48; 142-154.
3. Ozawa E, Nishino I, Nonaka I. Sarcolemmopathy: muscular dystrophies with cell membrane defects. Brain. Pathol. 2001; 11; 218-230.
4. Brown SC, Muntoni F, Sewry CA. Non-sarcolemmal muscular dystrophies. Brain Pathol. 2001; 11; 193-205.
5. Watkins SC, Cullen MJ, Hoffman EP, Billington L. Plasma membrane cytoskeleton of muscle: a fine structural analysis. Microsc. Res. Techn. 2000; 48; 131-141.
6. Tews DS, Goebel HH. DNA-fragmentation and expression of apoptosis-related proteins in muscular dystrophies. Neuropathol. Appl. Neurobiol. 1997; 23; 331-338.
7. Wakayama Y, Inoue M, Kojima H et al. Ultrastructural localization of alpha-, beta- and gamma-sarcoglycan and their mutual relation, and their relation to dystrophin, beta-dystroglycan and beta-spectrin in normal skeletal myofiber. Acta Neuropathol 1999; 97; 288-296.
8. Draviam R., Billington L, Senchak A, Hoffman EP, Watkins SC. Confocal analysis of the dystrophin protein complex in muscular dystrophies. Muscle Nerve 2001; 24; 262-272.
9. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987; 50; 509-517.
10. Reitter B, Goebel HH. Dystrophinopathies. Semin. Pediatr. Neurol. 1996; 3; 99-109.
11. Klein CJ, Coovert DD, Bulman DE et al. Somatic reversion/ suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am. J. Hum. Genet. 1992; 50; 950-959.
12. Thanh LT, Nguyen TM, Helliwell TR, Morris GE. Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. Am. J. Hum. Genet. 1995; 56; 725-731.
13. Medori R., Brooke MH, Waterston RH. Two dissimilar brothers with Becker's dystrophy have an identical genetic defect. Neurology 1989; 39; 1493-1496.
14. Gangopadhyay SB, Sherratt TG, Heckmatt JZ et al. Dystrophin in frameshift deletion patients with Becker muscular dystrophy. Am. J. Hum. Genet. 1992; 51; 331-334.
15. Vainzof M, Passos-Bueno MR, Pavanello RC, Zatz M. Is dystrophin always altered in Becker muscular dystrophy patients? J. Neurol. Sci. 1995; 131; 99-104.
16. Bushby KMD, Goodship JA, Nicholson LVB, Johnson MA, Haggerty ID, Gardner-Medwin D. Variability in clinical, genetic and protein abnormalities in manifesting carriers of Duchenne and Becker muscular dystrophy. Neuromuscul. Disord. 1993; 3; 57-64.
17. Pegoraro E, Schimke RN, Garcia C et al. Genetic and biochemical normalization in female carriers of Duchenne muscular dystrophy: evidence for failure of dystrophin production in dystrophin-competent myonuclei. Neurology 1995; 45; 677-690.
18. Matthews PM, Benjamin D, Van Bakel I et al. Muscle X-inactivation patterns and dystrophin expression in Duchenne muscular dystrophy carriers. Neuromuscul Disord. 1995; 5; 209-220.
19. Houfflin-Debarge V, Delsalle A, Subtil D, Mannessier L, Codaccioni X, Puech F. Fetal cells in the maternal blood: a step towards non-invasive prenatal diagnosis? Review of the literature. J. Gynecol. Obstet. Biol. Reprod. 1998; 27; 483-493.
20. Abbs S. Prenatal diagnosis of Duchenne and Becker muscular dystrophy. Prenat. Diagn. 1996; 16; 1187-1198.
21. Beggs AH, Koenig M, Boyce L, Kunkel LM. Detection of 98% of DMD/BMD gene deletions by PCR. Hum. Genet. 1990; 86; 45-46.
22. Philip N, Voelckel MA, Girardot L et al. La biologie moléculaire dans le conseil génétique des myopathies de Duchenne et de Becker. Pédiarie 1992; 47; 821-828.
23. Heckel S, Favre R, Flori J et al. In utero fetal muscle biopsy: a precious aid for the prenatal diagnosis of Duchenne muscular dystrophy. Fetal Diagn. Ther. 1999; 14; 127-132.
24. Ohlendieck K, Matsumura K, Ionasescu VV et al. Duchenne muscular dystrophy: deficiency of dystrophin-associated proteins in the sarcolemma. Neurology 1993; 43; 795-800.
25. Matsumura K, Burghes AHM, Mora M et al. Immunohistochemical analysis of dystrophin-associated proteins in Becker/Duchenne muscular dystrophy with huge in-frame deletions in the NH2-terminal and rod domains of dystrophin. J. Clin. Invest. 1994; 93; 99-105.
26. Di Blasi C, Morandi L, Barresi R, Blasevich F, Cornelio F, Mora M. Dystrophin-associated protein abnormalities in dystrophin-deficient muscle fibers from symptomatic and asymptomatic Duchenne/Becker muscular dystrophy carriers. Acta Neuropathol. 1996; 92; 369-377.
27. Takemitsu M, Nonaka I, Sugita H. Dystrophin-related protein in skeletal muscles in neuromuscular disorders: immunohistochemical study. Acta Neuropathol. 1993; 85; 256-259.
28. Sahashi K, Ibi T, Suoh H et al. Immunostaining of dystrophin and utrophin in skeletal muscle of dystrophinopathies. Intern. Med. 1994; 33; 277-283.
29. Minetti C, Sotgia F, Bruno C et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat. Genet. 1998; 18; 365-368.
30. Hagiwara Y, Sasaoka T, Araishi K et al. Caveolin-3 deficiency causes muscle degeneration in mice. Hum. Mol. Genet. 2000; 9; 3047-3054.
31. Galbiati F, Engelmann JA, Volonte D et al. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. J. Biol. Chem. 2001; 276; 21425-21433.
32. Galbiati F, Volonte D, Minetti C, Chu JB, Lisanti MP. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex. J. Biol. Chem. 1999; 274; 25632-25641.
33. Minetti C, Bado M, Broda P et al. Impairment of caveolae formation and T-system disorganization in human muscular dystrophy with caveolin-3 deficiency. Am. J. Pathol. 2002; 160; 265-270.
34. Hermann R, Straub V, Blank M et al. Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy. Hum. Mol. Genet. 2000; 9; 2335-2340.
35. Matsuda C, Hayashi YK, Ogawa M et al. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. Hum. Mol. Genet. 2001; 10; 1761-1766.
36. Repetto S, Bado M, Broda P et al. Increased number of caveolae and caveolin-3 overexpression in Duchenne muscular dystrophy. Biochem. Biophys. Res. Commun. 1999; 261; 547-550.
37. Betz RC, Schoser BG, Kaspar D et al. Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat. Genet. 2001; 28; 218-219.
38. Fischer D, Schroers A, Blumcke I et al. Consequences of a novel caveolin-3 mutation in a large German family. Ann. Neurol. 2003; 53; 233-241.
39. Tateyama M, Aoki M, Nishino I et al. Mutations in the caveolin-3 gene causes a peculiar form of distal myopathy. Neurology 2002; 58; 323-325.
40. Merlini L, Carbone I, Capanni C et al. Familial isolated hyperCKaemia associated with a new mutation in the caveolin-3 (CAV-3) gene. J. Neurol. Neurosurg. Psychiatry 2002; 73; 65-67.
41. Anderson LV, Davison K, Moss JA et al. Dysferlin is a plasma membrane protein and is expressed early in human development. Hum. Mol. Genet. 1999; 8; 855-861.
42. Selcen D, Stilling G, Engel AG. The earliest pathologic alterations in dysferlinopathies. Neurology 2001; 12; 1472-1481.
43. Bansal D, Miyake K, Vogel SS et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003; 423; 168-172.
44. Saito A, Higushi I, Nakagawa M et al. Miyoshi myopathy patients with novel 5′ splicing donor site mutation showed different dysferlin immunostaining at the sarcolemma. Acta Neuropathol. 2002; 104; 615-620.
45. Anderson LV, Harrison RM, Pogue R et al. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul. Disord. 2000; 10; 553-559.
46. Ho M, Gallardo E, McKenna-Yasek D, De Luna N, Ilia I, Brown RH Jr. A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Ann. Neurol. 2002; 51; 129-133.
47. Liu J, Aoki M, Ilia I et al Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat. Genet. 1998; 20; 31-36.
48. Illarioshkin SN, Ivanova-Smolenskaya IA, Greenberg CR et al. Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy. Neurology 2000; 55; 1931-1933.
49. Mahjneh I, Marconi G, Bushby K, Anderson IV, Tolvanen-Mahjneh H, Somer H. Dysferlinopathy (LGMD2B): a 23-year follow-up study of 10 patients homozygous for the same frameshifting dysferlin mutations. Neuromuscul. Disord. 2001; 11; 20-26.
50. Ilia I, Serrano-Munuera C, Gallardo E et al. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann. Neurol. 2001; 49; 130-134.
51. Ueyama H, Kumamoto T, Horinouchi H, Fujimoto S, Aono H, Tsuda T. Clinical heterogeneity in dysferlinopathy. Intern. Med. 2002; 41; 532-536.
52. Gallardo E, Rojas-Garcia R, de Luna N, Pou A, Brown RH Jr, Illa I. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001; 57; 2136-2138.
53. Matsumura K, Tomé FM, Collin H et al. Deficiency of the 50 kD dystrophin-associated glycoprotein in severe childhood autosomal recessive muscular dystrophy. Nature 1992; 359; 320-322.
54. Roberts SL, Anderson RD, Ibraghimov-Beskrovnaya O, Campbell KP. Primary structure and muscle-specific expression of the 50-kDa dystrophin-associated glycoprotein (adhalin). J. Biol. Chem. 1993; 268; 23739-23742.
55. Lim LE, Duclo F, Broux O et al. Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat. Genet. 1995; 11; 257-265.
56. Bönnemann CG, Modi R, Nogushi S et al. Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat. Genet. 1995; 11; 266-273.
57. Nogushi S, McNally EM, Ben Othmane K et al. Mutations in the dystrophin-asssociated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science 1995; 270; 819-822.
58. Nigro V, de Sa Moreira E, Piluso G et al. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat. Genet. 1996; 14; 195-198.
59. Sewry CA, Taylor J, Anderson LVB et al. Abnormalities in α-, β-, and γ-sarcoglycan in patients with limb-girdle muscular dystrophy. Neuromuscul. Disord. 1996; 6; 467-474.
60. Bönnemann CG, Wong J, Jones KJ et al. Primary gamma- sarcoglycanopathy (LGMD 2C): broadening of the mutational spectrum guided by the immunohistochemical profile. Neuromuscul. Disord. 2002; 12; 273-280.
61. Zimprich A, Grabowski M, Asmus F et al. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat. Genet. 2001; 29; 66-69.
62. Wheeler MT, Zarnegar S, McNally EM. ζ-sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy. Hum. Mol. Genet. 2002; 11; 2147-2154.
63. Piccolo F, Roberts SL, Jeanpierre M et al. Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity. Nat. Genet. 1995; 10; 243-245.
64. Takano A, Bönnemann CG, Honda H, Feener C, Kunkel LM, Sobue G. Intrafamilial phenotypic variation in limb-girdle muscular dystrophy 2C with compound heterozygous mutations. Muscle Nerve 2000; 23; 807-810.
65. Vainzof M, Passos-Bueno MR, Canovas M et al. The sarcoglycan complex in the six autosomal recessive limb-girdle muscular dystrophies. Hum. Mol. Genet. 1996; 5; 1963-1969.
66. Pogue R, Anderson LV, Pyle A et al. Strategy for mutation analysis in the autosomal recessive limb-girdle muscular dystrophies. Neuromuscul. Disord. 2001; 11; 80-87.
67. Iwata Y, Nakamura H, Mizuno Y et al. Defective association of dystrophin with sarcolemmal glycoproteins in the cardiomyopathic hamster heart. FEBS Lett. 1993; 329; 227-231.
68. Tomé FM, Evangelista T, Leclerc A et al. Congenital muscular dystrophy with merosin deficiency. C. R. Acad. Sci. [III] 1994; 317; 351-357.
69. Hillaire D, Leclerc A, Fauré S et al. Localization of merosin-negative congenital muscular dystrophy to chromosome 6q2 by homozygosity mapping. Hum. Mol. Genet. 1994; 3; 1657-1661.
70. Philpot J, Sewry C, Pennock J, Dubowitz V. Clinical phenotype in congenital muscular dystrophy: correlation with expression of merosin in skeletal muscle. Neuromuscul. Disord. 1995; 5; 301-305.
71. Lamer S, Carlier RY, Pinard JM et al. Congenital muscular dystrophy: use of brain MR imaging findings to predict merosin deficiency. Radiology 1998; 6; 811-816.
72. Allamand V, Sunada Y, Salih MA et al. Mild congenital muscular dystrophy in two patients with an internally deleted laminin alpha2-chain. Hum. Mol. Genet. 1997; 6; 747-752.
73. DiBlasi C, He Y, Morandi L, Cornelio F, Guicheney P, Mora M. Mild muscular dystrophy due to a nonsense mutation in the LAMA2 gene resulting in exon skipping. Brain 2001; 124; 698-704.
74. Minetti C, Bado M, Morreale G, Pedemonte M, Cordone G. Disruption of muscle basal lamina in congenital muscular dystrophy with merosin deficiency. Neurology 1996; 46; 1354-1358.
75. Vachon PH, Xu H, Liu L et al. Integrins (alpha7beta1) in muscle function and survival. Disrupted expression in merosin-deficient congenital muscular dystrophy. J. Clin. Invest. 1997; 100; 1870-1881.
76. Hodges BL, Hayashi YK, Nonaka I, Wang W, Arahata K, Kaufmann SJ. Altered expression of the alpha7beta1 integrin in human and murine muscular dystrophies. J. Cell. Sci. 1997; 110; 2873-2881.
77. Cohn RD, Mayer U, Saher G et al. Secondary reduction of alpha7B integrin in laminin alpha 2 deficient congenital muscular dystrophy supports an additional transmembrane link in skeletal muscle. J. Neurol. Sci. 1999; 163; 140-152.
78. Brockington M, Sewry CA, Herrmann R et al. Assignment of a form of congenital muscular dystrophy with secondary merosin deficiency to chromosome 1q42. Am. J. Hum. Genet. 2000; 66; 428-435.
79. Marbini A, Bellonoa MF, Ferrari A, Lodesani M, Gemignani F. Immunohistochemical study of merosin-negative congenital muscular dystrophy: laminin α2 deficiency in skin biopsy. Acta Neuropathol. 1997; 94; 103-108.
80. Vignier N, Moghadaszadeh B, Gary F, Beckmann J, Mayer U, Guicheney P. Structure, genetic localization, and identification of the cardiac and skeletal muscle transcripts of the human integrin α7 gene (ITGA7). Biochem. Biophys. Res. Commun. 1999; 260; 357-364.
81. Hayashi YK, Chou FL, Engvall E et al. Mutations in the integrin α7 gene cause congenital myopathy. Nat. Genet. 1998; 19; 94-97.
82. Pegoraro E, Cepollaro F, Prandini P et al. Integrin alpha 7 beta 1 in muscular dystrophy/myopathy of unknown etiology. Am. J. Pathol. 2002; 160; 2135-2143.
83. Bertini E, Pepe G. Collagen type VI and related disorders. Bethlem myopathy and Ullrich scleroatonic muscular dystrophy. Eur. J. Paediatr. Neurol. 2002; 6; 193-198.
84. Bethlem J, Wijngaarden GK. Benign myopathy, with autosomal dominant inheritance. A report on three pedigrees. Brain 1976; 99; 91-100.
85. Scacheri PC, Gillanders EM, Subramony SH et al. Novel mutations in collagen VI genes: expansion of the Bethlem myopathy phenotype. Neurology 2002; 58; 593-602.
86. Zhang RZ, Sabatelli P, Pan TC et al. Effects on collagen VI mRNA stability and microfibrillar assembly of three COL6A2 mutations in two families with Ullrich congenital muscular dystrophy. J. Biol. Chem. 2002; 277; 43557-43567.
87. Speer MC, Tandan R, Rao PN et al. Evidence for locus heterogeneity in the Bethlem myopathy and linkage to 2q37. Hum. Mol. Genet. 1996; 5; 1043-1046.
88. Speer MC, Vance JM, Lennon-Graham F et al. Exclusion of identified LGMD1 loci from four dominant limb-girdle muscular dystrophy families. Hum. Hered. 1998; 48; 179-184.
89. Pan TC, Zhang RZ, Pericak-Vance MA et al. Missense mutation in a von Willebrand factor type A domain of the alpha 3 (VI) collagen gene (COL6A3) in a family with Bethlem myopathy. Hum. Mol. Genet. 1998; 7; 807-812.
90. Vanegas OC, Zhang RZ, Sabatelli P et al. Novel COL6A1 splicing mutation in a family affected by mild Bethlem myopathy. Muscle Nerve 2002; 25; 513-519.
91. Lamande SR, Morgelin M, Selan C et al. Kinked collagen VI tetramers and reduced microfibril formation as a result of Bethlem myopathy and introduced triple helical glycin mutations. J. Biol. Chem. 2002; 277; 1949-1956.
92. Merlini L, Villanova M, Sabatelli P, Malandrini A, Maraldi NM. Decreased expression of laminin beta 1 in chromosome 21-linked Bethlem myopathy. Neuromusc. Disord. 1999; 9; 326-329.
93. Nagano A, Arahata K. Nuclear envelope proteins and associated disorders. Curr. Opin. Neurol. 2000; 13; 533-539.
94. Wilson KL. The nuclear envelope, muscular dystrophy and gene expression. Trends Cell Biol 2000; 10; 125-129.
95. Wehnert MS, Bonne G. The nuclear muscular dystrophies. Semin. Pediatr. Neurol. 2002; 9; 100-107.
96. Emery AEH. Emery-Dreifuss muscular dystrophy-a 40 year retrospective. Neuromuscul. Disord. 2000; 10; 228-232.
97. Bione S, Maestrini E, Rivella S et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat. Genet. 1994; 8; 323-327.
98. Tews DS. Emerin. Int. J. Biochem. Cell Biol. 1999; 31; 891-894.
99. Manilal S, Sewry CA, Pereboev A et al. Distribution of emerin and lamins in the heart and implications for Emery-Dreifuss muscular dystrophy. Hum. Mol. Genet. 1999; 8; 353-359.
100. Fairley EA, Riddell A, Ellis JA, Kendrick-Jones J. The cell cycle dependent mislocalisation of emerin may contribute to the Emery-Dreifuss muscular dystrophy phenotype. J. Cell Sci. 2002; 115; 341-354.
101. Manilal S, Recan D, Sewry CA et al. Mutations in Emery-Dreifuss muscular dystrophy and their effects on emerin protein expression. Hum. Mol. Genet. 1998; 7; 855-864.
102. Sabatelli P, Squarzoni S, Petrini S et al. Oral exfoliative cytology for the non-invasive diagnosis in X-linked Emery-Dreifuss muscular dystrophy patients and carriers. Neuromuscul. Disord. 1998; 8; 67-71.
103. Fidzianska A, Toniolo D, Hausmanowa-Petrusewicz I. Ultrastructural abnormalities of sarcolemmal nuclei in Emery-Dreifuss muscular dystrophy (EDMD). J. Neurol. Sci. 1998; 159; 88-93.
104. Ellis JA, Brown CA, Tilley LD, Kendrick-Jones J, Spence JE, Yates JR. Two distal mutations in the gene encoding emerin have profoundly different effects on emerin protein expression. Neuromuscul. Disord. 2000; 10; 24-30.
105. Manilal S, Sewry CA, Man N, Muntoni F, Morris GE. Diagnosis of X-linked Emery-Dreifuss muscular dystrophy by protein analysis of leucocytes and skin with monoclonal antibodies. Neuromuscul. Disord. 1997; 7; 63-66.
106. Tsuchiya Y, Hase A, Ogawa M, Yorifuji H, Arahata K. Distinct regions specify the nuclear membrane targeting of emerin, the responsible protein for Emery-Dreifuss muscular dystrophy. Eur. J. Biochem. 1999; 259; 859-865.
107. Bonne G, Di Barletta MR, Varnous S et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat. Genet. 1999; 21; 285-288.
108. Di Barletta MR, Ricci E, Galluzzi G et al. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am. J. Hum. Genet. 2000; 66; 1407-1412.
109. Stuurman N, Heins S, Aebi U. Nuclear lamins: their structure, assembly, and interactions. J. Struct. Biol. 1998; 122; 42-66.
110. Vaughan A, Alvarez-Reyes M, Bridger JM et al. Both emerin and lamin C depend on lamin C for localization at the nuclear envelope. J. Cell. Sci. 2001; 114; 2577-2590.
111. Muchir A, Bonne G, van der Kooi AJ et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum. Mol. Genet. 2000; 9; 1453-1459.
112. Fatkin D, MacRae C, Sasaki T et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N. Engl. J. Med. 1999; 341; 1759-1762.
113. Brodsky GL, Muntoni F, Miocic S, Sinagra G, Sewry C, Mestroni L. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation 2000; 101; 473-476.
114. Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum. Mol. Genet. 2000; 9; 109-112.
115. De Sandre-Giovannoli A, Chaoch M, Kozlov S et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am. J. Hum. Genet. 2002; 70; 726-736.
116. Bonne G, Mercuri E, Muchir A et al. Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Ann. Neurol. 2000; 48; 170-180.
117. Broers JL, Machiels BM, Kuijpers HJ et al. A- and B-type lamins are differentially expressed in normal human tissues. Histochem. Cell. Biol. 1997; 107; 505-517.
118. Brown SC, Ugol T, Torelli S, Feng L, Sewry CA, Muntoni F. Myoblast fusion is associated with marked changes in the nuclear lamina. Neuromuscul. Disord. 2000; 10; 361.
119. Sullivan T, Escalante-Alcalde D, Bhatt H et al. Loss of A-type lamin expression compromised nuclear envelope integrity leading to muscular dystrophy. J. Cell. Biol. 1999; 147; 913-920.
120. Sewry CA, Brown SC, Feng L, Morris GE, Muntoni F. Skeletal muscle pathology in patients with mutations in the lamin A/C gene. Neuromuscul. Disord. 2000; 10; 361.
121. Brais B, Bouchard JP, Xie YG et al. Short GCG expansion in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat. Genet. 1998; 18; 164-167.
122. Brais B, Rouleau GA, Bouchard JP, Fardeau M, Tomé FM. Oculopharyngeal muscular dystrophy. Semin. Neurol. 1999; 1; 59-66.
123. Müller T, Schroeder R, Zierz S. GCG repeats and phenotype in oculopharyngeal muscular dystrophy. Muscle Nerve 2001; 24; 120-122.
124. Hill ME, Creed GA, McMullan TF et al. Oculopharyngeal muscular dystrophy: phenotypic and genotypic studies in a UK population. Brain 2001; 124; 522-526.
125. Calado A, Tomé EM, Brais B et al. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly (A) binding protein 2 aggregates which sequester poly (A) RNA. Hum. Mol. Genet. 2000; 9; 2321-2328.
126. Tomé FM, Chateau D, Helbing-Leclerc A, Fardeau M. Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy. Neuromuscul. Disord. 1997; 7; S63-S69.
127. Uyama E, Tsukahara T, Goto K et al. Nuclear accumulation of expanded PABP2 gene product in oculopharyngeal muscular dystrophy. Muscle Nerve 2000; 23; 1549-1554.
128. Salmikangas P, Mykkanen OM, Gronholm M et al. Myotilin, a novel sarcomeric protein with two Ig-like domains, is encoded by a candidate gene for limb-girdle muscular dystrophy. Hum. Mol. Genet. 1999; 8; 1329-1336.
129. Van der Ven PF, Wiesner S, Salmikangas P et al. Interactions for a novel muscular dystrophy pathway. Gamma-filamin, the muscle-specific filamin isoform, interacts with myotilin. J. Cell Biol. 2000; 151; 235-248.
130. Mologni L, Salmikangas P, Fougerousse F, Beckmann JS, Carpen O. Developmental expression of myotilin, a gene mutated in limb-girdle muscular dystrophy type 1A. Mech. Dev. 2001; 103; 121-125.
131. Salmikangas P, van der Ven PF, Lalowski M et al. Myotilin, the limb-girdle muscular dystrophy 1A (LGMD1A) protein, cross-links actin filaments and controls sarcomere assembly. Hum. Mol. Genet. 2003; 12; 189-203.
132. Hauser MA, Korrigan SK, Salmikangas P et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum. Mol. Genet. 2000; 9; 2141-2147.
133. Hauser MA, Conde CB, Kowaljow V et al. Myotilin mutations found in second pedigree with LGMD1A. Am. J. Hum. Genet. 2002; 71; 1428-1432.
134. Valle G, Faulkner G, De Antoni A et al. Telethonin, a novel sarcomeric protein of heart and skeletal muscle. FEBS Lett. 1997; 415; 163-168.
135. 2 terminus of titin spans the Z-disc: its interaction with a novel 19-kD ligand (T-cap) is required for sarcomeric integrity. J. Cell Biol. 1998; 143; 1013-1027.
136. Mues A, van der Ven PF, Young P, Furst DO, Gautel M. Two immunoglobulin-like domains of the Z-disc portion of titin interact in a conformation-dependent way with telethonin. FEBS Lett. 1998; 428; 111-114.
137. Gregorio CC, Granzier H, Sorimachi H, Labeit S. Muscle assembly: a titanic achievement? Curr. Opin. Cell Biol. 1999; 11; 18-25.
138. Zou P, Gautel M, Geerlof A, Wilmanns M, Koch MH, Svergun DI. Solution scattering suggests cross-linking function of telethonin in the complex with titin. J. Biol. Chem. 2003; 278; 2636-2344.
139. Moreira ES, Wiltshire TJ, Faulkner G et al. Limb-girdle muscular dystrophy 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nat. Genet. 2000; 24; 163-166.
140. Zatz M, Vainzof M, Passos-Bueno MR. Limb-girdle muscular dystrophy: one gene with different phenotypes, one phenotype with different genes. Curr. Opin. Neurol. 2000; 13; 511-517.
141. Vainzof M, Moreira ES, Suzuki OT et al. Telethonin protein expression in neuromuscular disorders. Biochim. Biophys. Acta 2002; 1588; 33-40.
142. Udd B, Haravuori H, Kalimo H et al. Tibial muscular dystrophy-from clinical description to linkage on chromosome 2q31. Neuromuscul. Disord 1998; 8; 327-332.
143. Haravuori H, Vihola A, Straub V et al. Secondary calpain3 deficiency in 2q-linked muscular dystrophy. Titin is the candidate gene. Neurology 2001; 56; 869-877.
144. Hackman P, Vihola A, Haravuori H et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am. J. Hum. Genet. 2002; 71; 492-500.
145. Garvey SM, Rajan C, Lerner AP, Frankel WN, Cox GA. The muscular dystrophy with myositis (mdm) mouse mutation disrupts a skeletal muscle-specific domain of titin. Genomics 2002; 79; 146-149.
146. Richard I, Broux O, Allamand V et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995; 81; 27-40.
147. Ono Y, Shimada H, Sorimachi H et al. Functional defects of a muscle-specific calpain, p94, caused by mutations associated with limb-girdle muscular dystrophy 2A. J. Biol. Chem. 1998; 273; 17073-17078.
148. Richard I, Roudaut C, Saenz A et al. Calpainopathy-a survey of mutations and polymorphisms. Am. J. Hum. Genet. 1999; 64; 1524-1540.
149. Pollitt C, Anderson LV, Pogue R, Davison K, Pyle A, Bushby KM. The phenotype of calpainopathy: diagnosis based on a multidisciplinary approach. Neuromuscul. Disord. 2001; 11; 287-296.
150. Chae J, Minami N, Jin Y et al. Calpain 3 gene mutations: genetic and clinico-pathologic findings in limb-girdle muscular dystrophy. Neuromuscul. Disord. 2001; 11; 547-555.
151. Sorimachi H, Kimura S, Kinbara K et al. Structure and physiological functions of ubiquitous and tissue-specific calpain species. Muscle-specific calpain, p94, interacts with connectin/titin. Adv. Biophys. 1996; 33; 101-122.
152. Ono Y, Sorimachi H, Suzuki K. New aspects of the research on limb-girdle muscular dystrophy 2A: a molecular biologic and biochemical approach to pathology. Trends Cardiovasc. Med. 1999; 9; 114-118.
153. Topaloglu H, Dincer P, Richards I et al. Calpain-3 deficiency causes a mild muscular dystrophy in childhood. Neuropediatrics 1997; 28; 212-216.
154. Urtasun M, Saenz A, Roudaut C et al. Limb-girdle muscular dystrophy in Guipuzcoa (Basque Country, Spain). Brain 1998; 121; 1735-1747.
155. Fanin M, Pegoraro E, Matsuda-Asada C, Brown RH Jr, Angelini C. Calpain-3 and dysferlin protein screening in patients with limb-girdle dystrophy and myopathy. Neurology 2001; 56; 660-665.
156. Spencer MJ, Tidball JG, Anderson LV et al. Absence of calpain 3 in a form of limb-girdle muscular dystrophy (LGMD2A). J. Neurol. Sci. 1997; 146; 173-178.
157. Anderson LV, Davison K, Moss JA et al. Characterization of monoclonal antibodies to calpain 3 and protein expression in muscle from patients with limb-girdle muscular dystrophy type 2A. Am. J. Pathol. 1998; 153; 1169-1179.
158. Talim B, Ognibene A, Mattioli E, Richard I, Anderson LV, Merlini L. Normal calpain expression in genetically confirmed limb-girdle muscular dystrophy type 2A. Neurology 2001; 56; 692-693.
159. Kobayashi K, Nakahori Y, Miyake M et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998; 394; 388-392.
160. Toda T, Kobayashi K. Fukuyama-type congenital muscular dystrophy: the first human disease to be caused by an ancient retrotransposal integration. J. Mol. Med. 1999; 77; 816-823.
161. Kondo-Iida E, Kobayashi K, Watanabe M et al. Novel mutations and genotype-phenotype relationships in 107 families with Fukuyama-type congenital muscular dystrophy (FCMD). Hum. Mol. Genet. 1999; 8; 2303-2309.
162. Kobayashi K, Sasaki J, Kondo-Lida E et al. Structural organization, complete genomic sequences and mutational analyses of the Fukuyama-type congenital muscular dystrophy gene, fukutin. FEBS Lett. 2001; 489; 192-196.
163. Jong Y-J, Kobayashi K, Toda T et al. Genetic heterogeneity in three Chinese children with Fukuyama congenital muscular dystrophy. Neuromuscul Disord. 2000; 10; 108-112.
164. Aravind L, Koonin EV. The fukutin protein family-predicted enzymes modifying cell-surface molecules. Curr. Biol. 1999; 9; 836-837.
165. Saito Y, Mizuguchi M, Oka A, Takashima S. Fukutin protein is expressed in neurons of the normal developing brain but is reduced in Fukuyama-type congenital muscular dystrophy brain. Ann. Neurol. 2000; 47; 756-764.
166. Yamamoto T, Kato Y, Karita M et al. Fukutin expression in glial cells and neurons: implication in the brain lesions of Fukuyama congenital muscular dystrophy. Acta Neuropathol. 2002; 104; 217-224.
167. Izumi T, Kara K, Ogawa T et al. Abnormality of cerebral gangliosides in Fukuyama type congenital muscular dystrophy. Brain Dev. 1995; 17; 33-37.
168. Hayashi YK, Ogawa M, Tagawa K et al. Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 2001; 57; 115-121.
169. Sunada Y, Saito F, Higuchi I, Matsumura K, Shimizu T. Deficiency of a 180-kDa extracellular matrix protein in Fukuyama type congenital muscular dystrophy skeletal muscle. Neuromuscul. Disord. 2002; 12; 117-120.
170. Brockington M, Blake DJ, Prandini P et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin α2 deficiency and abnormal glycosylation of a α-dystroglycan. Am. J. Hum. Genet. 2001; 69; 1198-1202.
171. Brockington M, Yuva Y, Prandini P et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum. Mol. Gen. 2001; 10; 2851-2859.
172. Brockington M, Blake DJ, Prandini P, Brown SC, Muntoni F. The gene for a novel glycosyltransferase is mutated in congenital muscular dystrophy MDC1C and limb girdle muscular dystrophy 2I. Neuromuscul. Disord. 2002; 12; 233-234.
173. Bushby K, Anderson LV, Pollitt C, Naom I, Muntoni F, Bindoff L. Abnormal merosin in adults. A new form of late onset muscular dystrophy not linked to chromosome 6q2. Brain 1998; 121; 581-588.
174. Frosk P, Weiler T, Nylen E et al. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32. a putative E3-ubiquitin-ligase gene. Am. J. Hum. Genet. 2002; 70; 663-672.
175. Banwell BL. Intermediate filament-related myopathies. Pediatr. Neurol. 2001; 24; 257-263.
176. Goebel HH, Warlo I. Surplus protein myopathies. Neuromuscul Disord. 2001; 11; 3-6.
177. De Bleecker JL, Engel AG, Ertl BB. Myofibrillar myopathy with abnormal foci of desmin positivity. II. Immunocytochemical analysis reveals accumulation
178. Caron A, Viader F, Lechevalier B, Chapon F. Cytoplasmic body myopathy: familial cases with accumulation of desmin and dystrophin. An immunohistochemical, immunoelectron microscopic and biochemical study. Acta Neuropathol. 1995; 90; 150-157.
179. Goebel HH, Voit T, Warlo I, Jacobs K, Johannsen U, Muller CR. Immunohistologic and electron microscopic abnormalities of desmin and dystrophin in familial cardiomyopathy and myopathy. Rev. Neurol. 1994; 150; 452-459.
180. Goudeau B, Dagvadorj A, Rodrigues-Lima F et al. Structural and functional analysis of a new desmin variant causing desmin-related myopathy. Hum. Mutat. 2001; 18; 388-396.
181. Dalakas MC, Park KY, Semino-Mora C, Lee HS, Sivakumur K, Goldfarb LG. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N. Engl. J. Med. 2000; 342; 770-780.
182. Goldfarb LG, Park KY, Cervenakova L et al. Missense mutations in desmin associated with familial cardic and skeletal myopathy. Nat. Genet. 1998; 19; 402-403.
183. Munoz-Marmol AM, Strasser G, Isamat M et al. A dysfunctional desmin mutation in a patient with severe generalized myopathy. Proc. Natl. Acad. Sci. USA 1998; 95; 11312-11317.
184. Vicart P, Caron A, Guicheney P et al. A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat. Genet. 1998; 20; 92-95.
185. Ferreiro A, Ceuterick-de Groote C, Marks JJ et al. Desmin-related myopathy with Mallory body-like inclusions is caused by mutation of the selenoprotein N gene. Ann. Neurol. 2004; 55; 676-686.
186. Tajsharghi H, Thornell L-E, Lindberg C et al. Myosin storage myopathy associated with a heterozygous missense mutation in MYH7. Ann. Neurol. 2003; 54; 494-500.
187. Nowak KJ, Wattanasirichaigoon D, Goebel HH et al. Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy. Nat. Genet. 1999; 23; 208-212.
188. Goebel HH, Warlo I. Progress in desmin-related myopathies. J. Child Neurol. 2000; 15; 565-572.
189. Osborn M, Goebel HH. The cytoplasmic bodies in a congenital myopathy can be stained with antibodies to desmin, the muscle-specific intermediate filament protein. Acta Neuropathol. 1983; 62; 149-152.
190. Rappaport L, Contard F, Samuel JL et al. Storage of phosphorylated desmin in a familial myopathy. FEBS Lett. 1988; 231; 421-425.
191. Vajsar J, Becker LE, Freedom RM, Murphy EG. Familial desminopathy: myopathy with accumulation of desmin-type intermediate filaments. J. Neurol. Neurosurg. Psychiatry 1993; 56; 644-648.
192. Baeta AM, Figarella-Branger D, Bille-Turc F, Lepidi H, Pellisier J-F. Familial desmin myopathies and cytoplasmic body myopathies. Acta Neuropathol. 1996; 92; 499-510.
193. Lobrinus JA, Janzer RC, Kuntzer T et al. Familial cardiomyopathy and distal myopathy with abnormal desmin accumulation and migration. Neuromuscul Disord. 1998; 8; 77-86.
194. Howman EV, Sullivan N, Poon EP, Britton JE, Hilton-Jones D, Davies KE. Syncoilin accumulation in two patients with desmin-related myopathy. Neuromuscul. Disord. 2003; 13; 42-48.
195. Wanschit J, Nakano S, Goudeau B et al. Myofibrillar (desmin-related) myopathy: clinico-pathological spectrum in 3 cases and review of the literature. Clin. Neuropathol. 2002; 21; 220-231.
196. Carlsson L, Fischer C, Sjoberg G, Robson RM, Sejersen T, Thornell LE. Cytoskeletal derangements in hereditary myopathy with a desmin L345P mutation. Acta Neuropathol. 2002; 104; 493-504.
197. Sewry CA, Brown SC, Pelin K et al. Abnormalities in the expression of nebulin in chromosome-2 linked nemaline myopathy. Neuromuscul. Disord. 2001; 11; 146-153.
198. Gurgel-Giannetti J, Reed U, Bang ML et al. Nebulin expression in patients with nemaline myopathy. Neuromuscul. Disord. 2001; 11; 154-162.
199. Durling HJ, Reilich P, Muller-Hocker J et al. De novo missense mutation in a constitutively expressed exon of the slow alpha-tropomyosin gene TPM3 associated with an atypical, sporadic case of nemaline myopathy. Neuromuscul. Disord. 2002; 12; 947-951.
200. Wattanasirichaigoon D, Swoboda KJ, Takada F et al. Mutations of the slow muscle alpha-tropomyosin gene, TPM3, are a rare cause of nemaline myopathy. Neurology 2002; 59; 613-617.
201. Donner K, Ollikainen M, Ridanpaa M et al. Mutations in the beta-tropomyosin (TPM2) gene-a rare cause of nemaline myopathy. Neuromuscul. Disord. 2002; 12; 151-158.
202. Johnston JJ, Kelley RI, Crawford TO et al. A novel nemaline myopathy in the Amish caused by a mutation in troponin T1. Am. J. Hum. Genet. 2000; 67; 814-821.
203. Ilkovski B, Cooper ST, Nowak K et al. Nemaline myopathy caused by mutations in the muscle alpha-skeletal-actin gene. Am. J. Hum. Genet. 2001; 68; 1333-1343.
204. Jungbluth H, Sewry CA, Brown SC et al. Mild phenotype of nemaline myopathy with sleep hypoventilation due to a mutation in the skeletal muscle alpha-actin (ACTA1) gene. Neuromuscul. Disord. 2001; 11; 35-40.
205. Selcen D, Krueger BR, Engel AG. Familial cardioneuromyopathy with hyaline masses and nemaline rods: A novel phenotype. Ann. Neurol. 2002; 51; 224-234.
206. Fidzianska A. 'Cap-disease'-a failure in the correct muscle fibre formation. J. Neurol. Sci. 2002; 201; 27-31.
207. Tews DS, Goebel HH. Inflammatory myopathies. Curr. Opin. Neurol. 1996; 9; 375-379.
208. Engel AG, Arahata K. Mononuclear cells in myopathies. Quantification of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, implications for the pathogenesis of the different inflammatory myopathies. Hum. Pathol. 1986; 17; 704-721.
209. Askanas V, Engel WK. New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies. Curr. Opin. Rheumatol. 1995; 7; 486-496.
210. Tews DS, Pongratz DE. Immunohistological analysis of sarcoid myopathy. J. Neurol. Neurosurg. Psychiatry 1995; 59; 322-325.
211. Caldwell CJ, Swash M, van der Walt JD, Geddes JF. Focal myositis: A clinicopathological study. Neuromuscul. Disord. 1995; 5; 317-321.
212. Englund P, Nennesmo I, Klareskog L, Lundberg IE. Interleukin-1 alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum. 2002; 346; 1044-1055.
213. Pedrol E, Grau JM, Casademont J et al. Idiopathic inflammatory myopathies. Immunohistochemical analysis of the major histocompatibility complex antigen expression, inflammatory infiltrate phenotype and activation cell markers. Clin. Neuropathol. 1995; 14; 179-184.
214. Appleyard ST, Dubowitz V, Dunn MJ, Rose ML. Increased expression of HLA-ABC class I antigens by muscle fibers in Duchenne muscular dystrophy, inflammatory myopathy and other neuromuscular disorders. Lancet 1985; 1; 361-363.
215. Englund P, Lindroos E, Nennesmo I, Klareskog L, Lundberg IE. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am. J. Pathol. 2001; 159; 1263-1273.
216. Tews DS, Goebel HH. Expression of cell adhesion molecules in inflammatory myopathies. J. Neuroimmunol. 1995; 59; 185-194.
217. Carota A, Pizzolato GP, Redard M, Gailloud P, Grau GE. Adhesion molecules in HIV-related and idiopathic polymyositis: immunohistochemical studies. Clin. Neuropathol. 1997; 16; 312-318.
218. Tews DS, Goebel HH. Cytokine expression profile in idiopathic inflammatory myopathies. J. Neuropathol. Exp. Neurol. 1996; 55; 342-347.
219. Authier FJ, Mhiri C, Chazaud B et al. Interleukin-1 expression in inflammatory myopathies: evidence of marked immunoreactivity in sarcoid granulomas and muscle fibres showing ischaemic and regenerative changes. Neuropathol. Appl. Neurobiol. 1997; 23; 132-140.
220. Isenberg DA. Immunoglobulin deposition in skeletal muscle in primary muscle disease. Q. J. Med. 1983; 207; 297-310.
221. Engel AG, Biesecker G. Complement activation on muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers. Ann. Neurol. 1982; 12; 289-296.
222. Cantrell DA, Smith KA. Transient expression of interleukin 2 receptors. Consequences for T cell growth. J. Exp. Med. 1983; 158; 1895-1911.
223. Pegoraro E, Mancias P, Swerdlow SH et al. Congenital muscular dystrophy with primary laminin α2 (merosin) deficiency presenting as inflammatory myopathy. Ann. Neurol. 1996; 40; 782-791.
224. McNally EM, Ly CT, Rosenmann H et al. Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation. Am. J. Med. Genet. 2000; 91; 305-312.
225. Arahata K, Ishihara T, Fukunaga H et al. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Muscle Nerve 1995; 2; S56-66.
226. Walsh F, Moore SE, Lake BD. Cell adhesion molecule N-CAM is expressed by denervated myofibres in Werdnig-Hoffman and Kugelberg-Welander type spinal muscular atrophies. J. Neurol. Neurosurg. Psychiatry 1987; 50; 439-442.
227. Figarella-Branger D, Nedelec J, Pellissier JF, Boucraut J, Bianco N, Rougon G. Expression of various isoforms of neural cell adhesive molecules and their highly polysialylated counterparts in diseased human muscles. J. Neurol. Sci. 1990; 98; 21-36.
228. Schoser BG, Goebel HH. Tenascin in denervated human muscle. J. Neurol. Sci. 1996; 139; 203-209.
229. Müller-Felber W, Küllmer K, Fischer P et al. Fibre type specific expression of Leu19-antigen and N-CAM in skeletal muscle in various stages after experimental denervation. Virchows Arch. A Pathol. Anat. Histopathol. 1993; 422; 277-283.
230. Tews DS, Goebel HH, Schneider I, Gunkel A, Stennert E, Neiss WF. Expression profile of stress proteins, intermediate filaments, and adhesion molecules in experimentally denervated and reinnervated rat facial muscle. Exp. Neurol. 1997; 146; 125-134.
231. Tews DS, Goebel HH. Apoptosis-related proteins in skeletal muscle fibers of spinal muscular atrophy. J. Neuropathol. Exp. Neurol. 1997; 56; 150-156.
232. Tews DS, Goebel HH, Meinck HM. DNA-fragmentation and apoptosis-related proteins of muscle cells in motor neuron disorders. Acta Neurol. Scand. 1997; 96; 380-386.